Protocol Ledger

NCT06542614 · Phase II · COMPLETED

Treatment of Moderate to Severe Plaque Psoriasis

Interventional Phase II clinical trial protocol NCT06542614 sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-27 Enrollment: 209 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06542614
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)209 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06542614
Protocol FieldVerified Registry Value
NCT IdentifierNCT06542614
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment209 participants (ACTUAL)
Registered Start Date2024-08-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI